Concordium Pharmaceuticals: JSKN022 IND application officially accepted by CDE.

Kangning Jerry Pharmaceuticals announced that the company's independently developed programmatic cell death ligand 1/ integrin v6 bispecific antibody conjugate drug JSKN022 has submitted a new drug clinical trial application and has been officially accepted by the China National Medical Products Administration Drug Evaluation Center. The company plans to conduct the first human clinical study of JSKN022 for the treatment of advanced malignant solid tumors.